Suppr超能文献

在无流感嗜血杆菌HMC-S外排机制的情况下,L22核糖体蛋白改变无法增加大环内酯类药物的最低抑菌浓度。

Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.

作者信息

Peric Mihaela, Bozdogan Bülent, Galderisi Chad, Krissinger Dan, Rager Terry, Appelbaum Peter C

机构信息

Department of Pathology, Hershey Medical Center, Mail code H083, 500 University Dr., Hershey, PA 17033, USA.

出版信息

J Antimicrob Chemother. 2004 Aug;54(2):393-400. doi: 10.1093/jac/dkh364. Epub 2004 Jul 8.

Abstract

BACKGROUND

Haemophilus influenzae HMC-C with high-level macrolide resistance after multi-step selection by clarithromycin reverted spontaneously and became hypersusceptible to macrolides.

OBJECTIVE

Determination of macrolide resistance mechanism(s) in hypersusceptible and hyperresistant strains.

METHODS

The presence of macrolide efflux in the strains was studied by radioactive erythromycin accumulation. Ribosomal mutations were investigated by sequencing. The possible role of acrAB clusters in macrolide resistance was studied by sequencing and expression analysis.

RESULTS

The parent strain had no ribosomal alteration, but both high-level resistant and hypersusceptible strains had R88P mutations in ribosomal protein L22. Radioactive macrolide accumulation studies pointed to the presence of macrolide efflux in the high-level resistant and parent strains, but not in the hypersusceptible derivative. Transformation of hypersusceptible strains using total DNA from the parent strain restored the macrolide efflux system in the hypersusceptible strain, which was confirmed by MIC levels and radioactive erythromycin accumulation similar to that of the mutant resistant strain. Analysis of sequence and transcription of acrAB gene clusters showed no significant differences between resistant and hypersusceptible derivatives.

CONCLUSION

Mutation in ribosomal protein L22 alone does not confer high-level macrolide resistance unless efflux is present.

摘要

背景

经克拉霉素多步筛选后具有高水平大环内酯类耐药性的流感嗜血杆菌HMC-C自发回复突变,对大环内酯类药物变得高度敏感。

目的

确定高度敏感和高度耐药菌株中的大环内酯类耐药机制。

方法

通过放射性红霉素积累研究菌株中大环内酯类药物外排情况。通过测序研究核糖体突变。通过测序和表达分析研究acrAB基因簇在大环内酯类耐药中的可能作用。

结果

亲本菌株无核糖体改变,但高水平耐药菌株和高度敏感菌株的核糖体蛋白L22均有R88P突变。放射性大环内酯类药物积累研究表明,高水平耐药菌株和亲本菌株存在大环内酯类药物外排,而高度敏感衍生物中不存在。用亲本菌株的总DNA转化高度敏感菌株可恢复高度敏感菌株中的大环内酯类药物外排系统,这通过与突变耐药菌株相似的最低抑菌浓度水平和放射性红霉素积累得到证实。acrAB基因簇的序列和转录分析显示,耐药和高度敏感衍生物之间无显著差异。

结论

单独的核糖体蛋白L22突变不会导致高水平大环内酯类耐药,除非存在外排。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验